VRCA — Verrica Pharmaceuticals Balance Sheet
0.000.00%
- $45.22m
- $43.93m
- $7.57m
Annual balance sheet for Verrica Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 65.5 | 70.4 | 34.3 | 69.5 | 46.3 |
Net Total Accounts Receivable | |||||
Net Total Receivables | — | — | 0.487 | 4.42 | 0.077 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Current Assets | 67.7 | 74.3 | 39.1 | 77.5 | 51.2 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 4.94 | 5.5 | 5.33 | 3.62 | 2.58 |
Other Long Term Assets | |||||
Total Assets | 74.2 | 80.1 | 44.7 | 81.6 | 54.1 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 39.5 | 46.1 | 3.46 | 17 | 29 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 41.2 | 47.5 | 4.69 | 61.8 | 64 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Other Equity | |||||
Total Equity | 33 | 32.6 | 40 | 19.8 | -9.86 |
Total Liabilities & Shareholders' Equity | 74.2 | 80.1 | 44.7 | 81.6 | 54.1 |
Total Common Shares Outstanding |